Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 6/20 | 0.59 |
| ▸ | NPFFR2 | Q9Y5X5 | 6/20 | 0.59 |
| ▸ | DRD2 | P14416 | 5/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23268368 | 1.00 | NPFFR1 (0.59) | NPFFR1NPFFR2DRD2SIGMAR1IDO1 | |
| SCHEMBL2348786 | 0.93 | NPFFR1 (0.64) | NPFFR1NPFFR2DRD2SIGMAR1IDO1 | |
| SCHEMBL2281940 | 0.86 | NPFFR1 (0.59) | NPFFR1NPFFR2DRD2SIGMAR1IDO1 | |
| SCHEMBL13238500 | 0.85 | NPFFR1 (0.60) | NPFFR1NPFFR2DRD2SIGMAR1IDO1 | |
| SCHEMBL4517495 | 0.84 | NPFFR1 (0.57) | NPFFR1NPFFR2DRD2SIGMAR1IDO1 | |
| SCHEMBL4508281 | 0.84 | NPFFR1 (0.57) | NPFFR1NPFFR2SIGMAR1IDO1ALDH1A1 | |
| SCHEMBL9181182 | 0.84 | NPFFR1 (0.57) | NPFFR1NPFFR2DRD2SIGMAR1IDO1 | |
| SCHEMBL14728238 | 0.84 | NPFFR1 (0.64) | NPFFR1NPFFR2DRD2SIGMAR1IDO1 | |
| SCHEMBL8572167 | 0.84 | NPFFR1 (0.56) | NPFFR1NPFFR2DRD2SIGMAR1IDO1 | |
| SCHEMBL17606266 | 0.83 | OPRL1 (0.49) | NPFFR1NPFFR2ALDH1A1CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111848577-B | N- (hetero) aryl-substituted heterocyclic derivatives useful in the treatment of diseases or conditions associated with the central nervous system | 克罗诺斯治疗有限公司 | 2023-09-01 | — | — | CN | disclosed |
| US-11597733-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2023-03-07 | — | — | US | disclosed |
| WO-2021078120-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-29 | — | — | WO | disclosed |
| US-20210115065-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-22 | — | — | US | disclosed |
| EP-3194385-B3 | N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM | CHRONOS THERAPEUTICS LTD (GB) | 2021-02-17 | — | — | EP | disclosed |
| CN-111848577-A | N- (hetero) aryl-substituted heterocyclic derivatives useful for the treatment of diseases or disorders associated with the central nervous system | 克罗诺斯治疗有限公司 | 2020-10-30 | — | — | CN | disclosed |
| CN-107001318-B | N- (hetero) aryl-substituted heterocyclic derivatives useful for the treatment of diseases or disorders associated with the central nervous system | 克罗诺斯治疗有限公司 | 2020-08-11 | — | — | CN | disclosed |
| EP-3194385-B1 | N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM | CHRONOS THERAPEUTICS LTD (GB) | 2018-06-20 | — | — | EP | disclosed |
| US-9920053-B2 | N-(hetero)aryl-substituted heteroyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system | CHRONOS THERAPEUTICS LIMITED (GB) | 2018-03-20 | — | — | US | disclosed |
| US-20170253592-A1 | N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM | SHIRE INTERNATIONAL GMBH (CH) | 2017-09-07 | — | — | US | disclosed |
| US-7582627-B2 | 3-Amino-7-[3-(1-aminoethyl)-4-fluoropyrrolidin-1-yl]-1-cyclopropyl-8-methyl-1H-pyrido[4,3-d]pyrimidine-2,4-dione; quinolone antibiotics; bactericides; for antibiotic- resistant bacterial infections, ciprofloxacin- resistant ones; inhibiting wild-type and quinolone- resistant mutants of DNA gryase | WARNER-LAMBERT COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1255739-B1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | WARNER LAMBERT CO (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20060287308-A1 | 3-Aminoquinazolin-2,4-dione antibacterial agents | ZOETIS WLC LLC | 2006-12-21 | — | — | US | disclosed |
| US-7094780-B1 | 3-aminoquinazolin-2,4-dione antibacterial agents | WARNER LAMBERT COMPANY LLC (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060183762-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | ZOETIS WLC LLC | 2006-08-17 | — | — | US | disclosed |
| US-5854268-A | Azetidine, pyrrolidine and piperidine derivatives | MERCK SHARP & DOHME, LTD. (GB) | 1998-12-29 | — | — | US | disclosed |
| US-5453422-A | Animal growth promoters | BAYER AKTIENGESELLSCHAFT (DE) | 1995-09-26 | — | — | US | disclosed |
| US-5284842-A | Active against gramnegative bacteria | BAYER AKTIENGESELLSCHAFT (DE) | 1994-02-08 | — | — | US | disclosed |
| US-5173484-A | Animal growth regulators | BAYER AKTIENGESELLSCHAFT (DE) | 1992-12-22 | — | — | US | disclosed |
| EP-0326916-A2 | Quinolone- and naphthyridone-carboxylic acid derivatives, method for their preparation and antibacterial agents and food additives containing them | BAYER AG (DE) | 1989-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183762-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | ABL1, NQO2, CBR3 | NPFFR1 781/4885NPFFR2 828/4885DRD2 81/4885 |
| US-11597733-B2 | Compounds and compositions for the treatment of parasitic diseases | ABCB11, SQLE, FURIN | NPFFR1 3942/4885NPFFR2 4268/4885DRD2 4723/4885 |
| US-20170253592-A1 | N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM | SLC6A3, SLC6A2, SLC6A19 | NPFFR1 445/4885NPFFR2 352/4885DRD2 30/4885 |
| US-20060287308-A1 | 3-Aminoquinazolin-2,4-dione antibacterial agents | ABL1, NQO2, AAAS | NPFFR1 785/4885NPFFR2 873/4885DRD2 82/4885 |
| US-20210115065-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | ABCB11, SQLE, FURIN | NPFFR1 3942/4885NPFFR2 4268/4885DRD2 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.